US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astellas Pharma, Inc.

9.35

+0.14001.52%

Volume:169.54K

Turnover:1.57M

Market Cap:17.41B

PE:125.75

High:9.38

Open:9.22

Low:8.98

Close:9.21

Loading ...

Overview Company News Filings

Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing

Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize

U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

Astellas Makes Announcement about Management Structure

U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer

Japanese Stocks Climb 1.2%

Sangamo Shares Rally Premarket on License Deal With Astellas

Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves

Apellis started at equal-weight at Morgan Stanley on geographic atrophy market

Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management

Astellas receives Complete Response Letter for Izervay, Apellis rallies

Should Value Investors Buy Astellas Pharma (ALPMY) Stock?

Trump victory is a win for Japan equities, a loss for China – analyst

Astellas Pharma's Cancer Drug Vyloy Gets FDA Approval

Astellas wins FDA nod for first-line gastric cancer therapy

Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALPMY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":9.35,"timestamp":1744920000000,"preClose":9.21,"halted":0,"volume":169535,"delay":15,"floatShares":1731101601,"shares":1861787075,"eps":0.074352,"marketStatus":"Closed Good Friday","change":0.14,"latestTime":"04-17 16:00:00 EDT Delay","open":9.22,"high":9.38,"low":8.98,"amount":1572591.387100002,"amplitude":0.043431,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":9.21,"volumeRatio":0.34287439711953455},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1731101601,"roa":"3.67%","roe":"-3.83%","lyrEps":0.062841,"volumeRatio":0.34287439711953455,"shares":1861787075,"dividePrice":0.506376,"high":9.38,"amplitude":0.043431,"preClose":9.21,"low":8.98,"week52Low":8.37,"pbRate":"1.66","psRate":"1.33","week52High":13.14,"institutionHeld":0,"latestPrice":9.35,"eps":0.074352,"divideRate":0.054158,"volume":169535,"delay":15,"ttmEps":0.074352,"open":9.22,"prevYearClose":9.66,"prevWeekClose":8.88,"prevMonthClose":9.66,"prevQuarterClose":9.66,"fiveDayClose":8.94,"twentyDayClose":9.87,"sixtyDayClose":9.45,"earningDate":1745424000000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517980901","title":"Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517980901","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517980901?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:02","pubTimestamp":1741233720,"startTime":"0","endTime":"0","summary":"- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions -. TOKYO, March 5, 2025 /PRNewswire/ -- Astellas Pharma Inc.  and YASKAWA Electric Corporation  signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the dual-arm robot \"Maholo.\" In addition, the joint venture will offer platform access to startups and academic institutions, fostering collaboration and innovation in the field of cell therapy.The planned joint venture will leverage Astellas' expertise in R&D and manufacturing for cell therapy and the dual arm robot \"Maholo,\" developed by YASKAWA's subsidiary, Robotic Biology Institute. The closing and establishment of the joint venture company are subject to certain closing conditions, including receipt of required regulatory approvals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-yaskawa-agree-establish-joint-040200778.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-yaskawa-agree-establish-joint-040200778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMF","BK4080","BK4161","BK4185","YASKF","BK4231","YASKY","ALPMY","JYNT","ADC"],"gpt_icon":0},{"id":"2514894973","title":"Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize","url":"https://stock-news.laohu8.com/highlight/detail?id=2514894973","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514894973?lang=en_us&edition=fundamental","pubTime":"2025-02-27 23:00","pubTimestamp":1740668400,"startTime":"0","endTime":"0","summary":"Awardees win a year of access to a prestigious life-science incubator in San Francisco and toAstellas expertise to further their research. Award helps biotech start-ups accelerate early drug discovery and research efforts. NORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. , and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the Astellas Future Innovator Prize. The competition offers entrepreneurial scientists and emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art Bay Area facilities and access to Astellas' research and development capabilities and business leaders.Entrepreneurial scientists, emerging life-science and biotechnology start-ups have until April 1, 2025 to enter the Astellas Future Innovator Prize by submitting their non-confidential company presentation, including a one-page executive summary here.Companies awarded an Astellas Future Innovator P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-mbc-biolabs-announce-sixth-150000583.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-mbc-biolabs-announce-sixth-150000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMY","BK4007","MBC","BK4086","ALPMF"],"gpt_icon":0},{"id":"2511532511","title":"U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511532511","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511532511?lang=en_us&edition=fundamental","pubTime":"2025-02-13 07:32","pubTimestamp":1739403120,"startTime":"0","endTime":"0","summary":"TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced the U.S. Food and Drug Administration  approved expanded U.S. Prescribing information for IZERVAY  for the treatment of geographic atrophy  secondary to age-related macular degeneration . As a result, IZERVAY is now approved without a limitation on duration of dosing—providing physicians and patients with greater flexibility when managing GA.The approval follows Astellas' resubmission of the supplemental New Drug Application  for IZERVAY on December 26, 2024, within days of meeting with the FDA to clarify the Agency's feedback provided in the Complete Response Letter  issued in November 2024.Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma\"We are pleased with the FDA's decision to extend the use of IZERVAY for longer-term administration—further solidifying IZERVAY's status as a trusted choice for thousands of GA patients since its launch in 2023. To date, IZERVAY rem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/u-fda-approves-expanded-label-233200789.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-fda-approves-expanded-label-233200789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU0056508442.USD","LU1988902786.USD","LU1951200564.SGD","BK4543","IE00BMPRXN33.USD","LU0109392836.USD","BK4554","LU2250418816.HKD","LU1880398471.USD","LU1303367103.USD","IE00BMPRXR70.SGD","LU1923623000.USD","LU0823434740.USD","LU1880398554.USD","ALPMF","IE00B5949003.HKD","LU0082616367.USD","ALPMY","IE0004445239.USD","LU0823421416.USD","BK4573","BK4121","LU0390134368.USD","BK4585","GFS","LU2054465674.USD","LU2458330243.SGD","LU2360106780.USD","CRL","LU1064131342.USD","ACP","LU1803068979.SGD","IE0009356076.USD","BK4007","LU0127658192.USD","LU1316542783.SGD","LU0823421333.USD","BK4530","BK4534","LU0823434583.USD","BK4141","LU0081259029.USD","LU1242518857.USD","BK4605","BK4566","LU0889565833.HKD","BK4529","LU2264538146.SGD","LU1852331112.SGD"],"gpt_icon":1},{"id":"2510356549","title":"Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo","url":"https://stock-news.laohu8.com/highlight/detail?id=2510356549","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510356549?lang=en_us&edition=fundamental","pubTime":"2025-02-12 03:13","pubTimestamp":1739301234,"startTime":"0","endTime":"0","summary":"On Monday, Pfizer Inc. and Astellas Pharma Inc.   released additional follow-up results from the Phase 3 EV-302 trial  of Padcev plus Keytruda  in patients with previously untreated locally advanced or metastatic urothelial cancer .Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook. The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy.The median OS was 33.8 months for the combination versus 15.9 months for chemotherapy.The OS benefit was observed in all prespecified subgroups, including cisplatin eligible and ineligible subgroups.The median PFS was 12.5 months for the combination versus 6.3 months for chemotherapy.In addition to longer follow-up data, an exploratory analysis evalu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-tout-encouraging-data-191354087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0306807586.USD","BK4592","LU0058720904.USD","LU1894683348.USD","LU0122379950.USD","BK4195","LU1066053197.SGD","ALPMF","LU1066051498.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","SG9999013999.USD","LU0985481810.HKD","PFS","LU0225771236.USD","BK4568","PFE","BK4581","LU1057294990.SGD","MRK","OS","IE0002270589.USD","SG9999001176.USD","BK4585","LU0170899867.USD","IE00BBT3K403.USD","LU1883839398.USD","IE00B19Z3581.USD","BK4007","LU0225284248.USD","LU0289739699.SGD","BK4588","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","IE00BLSP4239.USD","ALPMY","LU0321505868.SGD","BK4211","SG9999003800.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999011175.SGD","BK4550","BK4533","BK4097","LU1894683264.USD","IE000M9KFDE8.USD","BK4534","BK4599"],"gpt_icon":1},{"id":"2510815573","title":"Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510815573","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510815573?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:00","pubTimestamp":1739224800,"startTime":"0","endTime":"0","summary":"Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC. At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified. NEW YORK & TOKYO, February 10, 2025----Pfizer Inc.  and Astellas Pharma Inc.  today announced additional follow-up results from the Phase 3 EV-302 clinical trial  evaluating the efficacy and safety of PADCEV  , a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA , a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer . The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .1,2 These data will be p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b68b91779c1270fe944d25cf0021e5aa","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-padcev-enfortumab-vedotin-220000915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","BK4195","BK4585","LU0234572021.USD","ADC","BK4559","LU0321505868.SGD","LU1699723380.USD","BK4516","LU0208291251.USD","LU0985481810.HKD","LU1571399168.USD","LU1934455863.HKD","LU1983299246.USD","OS","BK4007","ALPMF","LU1023059063.AUD","MRK","LU1162221912.USD","LU0122379950.USD","LU1037948897.HKD","IE00BLSP4239.USD","LU1116320737.USD","TEN","LU0238689110.USD","IE00B2B36J28.USD","LU1929549753.HKD","LU0289739699.SGD","LU1883839398.USD","BK4097","IE0031619046.USD","LU2089984988.USD","AST","BK4157","PFE","PFS","LU0320765646.SGD","SG9999013999.USD","ALT","BK4080","LU0321505439.SGD","BK4534","IE00B66KJ199.SGD","IE0009355771.USD","LU1934455277.USD","ALPMY","AEIS","LU0861579265.USD","LU1057294990.SGD","LU1585245621.USD"],"gpt_icon":1},{"id":"2509474462","title":"Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2509474462","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509474462?lang=en_us&edition=fundamental","pubTime":"2025-02-05 16:59","pubTimestamp":1738745940,"startTime":"0","endTime":"0","summary":"- Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy  secondary to age-related macular degeneration  in Japan -. TOKYO, Feb. 5, 2025 /PRNewswire/ -- Astellas Pharma Inc.   today announced the submission of a New Drug Application  to Japan's Ministry of Health, Labour and Welfare  for Conditional Approval of avacincaptad pegol intravitreal solution , a synthetic aptamer that inhibits the complement C5 protein, for the treatment of GA secondary to AMD. If approved, ACP has the potential to become the first and only GA treatment available in Japan.About avacincaptad pegolAvacincaptad pegol  is an investigational drug for treatment of geographic atrophy  secondary to age-related macular degeneration  that has been submitted for Conditional Approval in Japan. ACP is approved in the U.S. as IZERVAY for the treatment of GA secondary to AMD.6 ACP is a synthetic aptamer that inhibits the complement C5 protein.8 Overa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-submits-drug-application-conditional-085900977.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-submits-drug-application-conditional-085900977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0056508442.USD","LU0823434583.USD","LU0889565833.HKD","LU1242518857.USD","LU2458330243.SGD","BK4141","LU1951200564.SGD","LU1064131342.USD","BK4585","LU0109392836.USD","BK4007","LU2054465674.USD","LU0823421416.USD","LU1316542783.SGD","BK4534","ALPMF","LU1951198990.SGD","IE0009356076.USD","LU0823434740.USD","LU2264538146.SGD","BK4532","LU2098885051.SGD","BK4543","LU1242518931.SGD","LU1852331112.SGD","LU0198837287.USD","LU0642271901.SGD","LU2360106780.USD","BK4566","GFS","LU0127658192.USD","IE00B5949003.HKD","LU1303367103.USD","ALPMY","LU1923623000.USD","LU0082616367.USD","BK4575","LU0390134368.USD","IE0004445239.USD","ACP","BK4573","LU2458330169.SGD","BK4512","BK4529","IE00BMPRXN33.USD","LU1880398554.USD","LU2250418816.HKD","IE00BMPRXR70.SGD","LU0979878070.USD","LU1989764664.SGD"],"gpt_icon":1},{"id":"2508489920","title":"Astellas Makes Announcement about Management Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2508489920","media":"PR Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508489920?lang=en_us&edition=fundamental","pubTime":"2025-02-04 14:30","pubTimestamp":1738650600,"startTime":"0","endTime":"0","summary":"TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced thatthe following changes to its management structure effective April 1, 2025.Regarding the Changes in Management StructureAstellas aims to create and deliver \"VALUE\" for patients. To promote drug discovery activities swiftly and efficiently from the early stages of research through to commercialization with patient-centric approach, Astellaswill change itsmanagement structure effective April 1, 2025, establishing new top management positions and making personnel changes as follows.Establishment and Appointment of Chief Research & Development Officer As an innovation engine, we will integrate the research and development teams, and the Primary Focus Leads to provide the next-generation groundbreaking therapies from Astellas. Effective April 1, 2025, we will establish the position of CRDO, overseeing these divisions, with Tadaaki Taniguchi, M.D., Ph.D., the current Chief Medical Officer , appointed to this role.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-makes-announcement-management-structure-063000131.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-makes-announcement-management-structure-063000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456855351.SGD","LU0306807586.USD","LU0823414551.USD","LU1093756325.SGD","LU0985481810.HKD","LU1989771016.USD","ALPMY","CMO","LU1868837300.USD","LU2290526834.HKD","BK4559","IE00BFTCPJ56.SGD","LU2360032135.SGD","LU1430594728.SGD","CEO","LU1861215975.USD","LU1585245621.USD","LU2294711713.HKD","LU1670710661.SGD","BK4581","CCO","LU2125154935.USD","BK4534","BK4588","LU1868836757.USD","LU0306806265.USD","ALPMF","BK4007","LU0823414478.USD","LU2242652126.USD","LU2506951792.HKD","LU0868494617.USD","BMY","LU1670710588.SGD","LU1323610961.USD","LU1868836914.USD","LU1074936037.SGD","LU1571399168.USD","LU2360107168.USD","LU2133065610.SGD","LU1718418525.SGD","LU2357125470.USD","LU0237698245.USD","CFO","LU0882574055.USD","LU0114720955.EUR","LU0096364046.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU0061475181.USD"],"gpt_icon":1},{"id":"2502870400","title":"U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2502870400","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502870400?lang=en_us&edition=fundamental","pubTime":"2025-01-09 07:30","pubTimestamp":1736379000,"startTime":"0","endTime":"0","summary":"TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced the U.S. Food and Drug Administration  accepted the revised supplemental New Drug Application  for IZERVAY  for the treatment of geographic atrophy  secondary to age-related macular degeneration  on January 6, 2025, in response to the Agency's November 2024Complete Response Letter . The application was refiled following a December 20, 2024, meeting between the FDA and Astellas and has been designated as a Class 1 resubmission, with a 60-day review period.IZERVAY was approved by the U.S. Food and Drug Administration on August 4, 2023, for the treatment of GA secondary to AMD.The sNDA seeks to add positive 2-year data to the IZERVAY U.S. Prescribing Information based on results from the GATHER2 Phase 3 clinical trial.The impact of this matteron Astellas' financial results for the fiscal year ending March 31, 2025, is expected to be minor.IZERVAY  is a prescription eye injection, used to treat geographic atrophy , t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/u-fda-confirms-class-1-233000210.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-fda-confirms-class-1-233000210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXN33.USD","BK4121","LU1951198990.SGD","BK4512","LU2250418816.HKD","LU0823434740.USD","LU1316542783.SGD","CRL","ACP","LU0198837287.USD","BK4588","LU0127658192.USD","BK4573","LU0823434583.USD","LU1989764664.SGD","BK4141","IE0009356076.USD","BK4007","LU2054465674.USD","BK4575","BK4566","LU0823421416.USD","LU0823421333.USD","LU1803068979.SGD","BK4534","LU0719512351.SGD","ALPMY","ALPMF","LU1951200564.SGD","LU1988902786.USD","LU0081259029.USD","LU0642271901.SGD","BK4529","LU2458330243.SGD","LU1880398554.USD","LU0082616367.USD","LU2458330169.SGD","LU1242518931.SGD","LU0390134368.USD","LU0979878070.USD","BK4530","LU1303367103.USD","IE00B5949003.HKD","LU1064131342.USD","IE0004445239.USD","LU2098885051.SGD","LU2264538146.SGD","LU1923623000.USD","LU1242518857.USD","GFS"],"gpt_icon":1},{"id":"2501742284","title":"China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501742284","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501742284?lang=en_us&edition=fundamental","pubTime":"2025-01-08 17:55","pubTimestamp":1736330100,"startTime":"0","endTime":"0","summary":"- First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care for nearly 40 years1. - NMPA approval based on the global Phase 3 EV-302 trial  where the treatment combination significantly improved overall survival and progression-free survival outcomes1. TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced that China's National Medical Products Administration  has approved PADCEV in combination with KEYTRUDA  for adult patients with locally advanced or metastatic urothelial cancer . The treatment combination willprovide a new therapeutic option to patients with la/mUC in Chinaand offer an alternative to platinum-containing chemotherapy, the standard of care for nearly 40 years.1. Professor Huang Jian, Lead Primary Investigator of the EV-302 Study in China, Chairman of the Urology Subcommittee of the Chinese Medical Association, Depart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0942090050.USD","LU0306806265.USD","LU1917777945.USD","BK4579","LU0985481810.HKD","SG9999003800.SGD","IE00BSNM7G36.USD","BK4097","PFE","IE0002141913.USD","BK4599","LU1291159041.SGD","IE0009355771.USD","LU2237443382.USD","OS","LU2112291526.USD","SG9999001176.SGD","LU1037948897.HKD","BK4550","LU0320765489.SGD","LU0203345920.USD","LU0950375773.USD","LU1066051811.HKD","LU0321505439.SGD","NHLD","IE00B3PB1722.GBP","LU0306807586.USD","PFS","SG9999015341.SGD","LU1244550577.SGD","IE00BVYPNV92.GBP","IE00BFMHRM44.USD","ALPMY","LU1093756168.USD","LU1989772923.USD","MRK","SG9999014542.SGD","LU0265550359.USD","LU0965509101.SGD","IE00B19Z3B42.SGD","LU1894683264.USD","AEIS","LU0965509010.AUD","LU2361044865.SGD","CSCO","ADC","SG9999014567.USD","ALPMF","LU1941712348.USD","SG9999001440.SGD","LU2506952097.USD"],"gpt_icon":1},{"id":"2493789064","title":"Japanese Stocks Climb 1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493789064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493789064?lang=en_us&edition=fundamental","pubTime":"2024-12-23 15:00","pubTimestamp":1734937200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Stocks in Japan gained Monday, as the Nikkei Stock Average rose 1.2% to 39161.34.Mitsubishi Motors Corp. was the biggest gainer during the session, surging 5.3% to Y491, and Advantest Corp. surged 4.5% to Y9,000. IHI Corp. rounded out the top three movers, as shares gained 4.3% to Y8,709.Astellas Pharma Inc. posted the largest decline, falling 1.5% to Y1,519, followed by shares of Rakuten Group Inc., which fell 1.4% to Y907. Shares of BANDAI NAMCO Holdings Inc. fell 1.4% to Y3,720.On the currency front, the yen weakened 0.1% against the dollar to Y156.64.In the bond markets, the two-year Japanese government bond yield rose 0.27 basis point to 0.580% and the 10-year JGB yield rose 0.63 basis point to 1.061%. In the U.S., the 10-year Treasury yield rose 0.50 basis point to 4.524%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US12M.BOND","IHICY","US7Y.BOND","US2Y.BOND","ALPMY","MMTOY","BK4007","US10Y.BOND","US30Y.BOND","US3Y.BOND","US5Y.BOND","US6M.BOND","BK4161"],"gpt_icon":0},{"id":"2492258861","title":"Sangamo Shares Rally Premarket on License Deal With Astellas","url":"https://stock-news.laohu8.com/highlight/detail?id=2492258861","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492258861?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:20","pubTimestamp":1734607200,"startTime":"0","endTime":"0","summary":"Shares of Sangamo Therapeutics rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with Japan's Astellas Pharma.Sangamo said it will receive a $20 million upfront license fee from Astellas and will be eligible to earn up to an additional $1.3 billion in licensed target fees and milestone payments under the agreement, along with royalties on sales of products emerging from the deal.The Richmond, Calif., company said the agreement gives Astellas a license to use its novel proprietary capsid, STAC-BBB, for one neurological disease target, with the right to add up to four more targets.Sangamo shares, which closed Wednesday at $2.35, were recently up 23% to $2.90 in premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALPMY","BK4139","BK4007","BK4556","SGMO"],"gpt_icon":0},{"id":"2489345456","title":"Astellas and Dr. Jen Ashton launch \"Cooler Moments\" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves","url":"https://stock-news.laohu8.com/highlight/detail?id=2489345456","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489345456?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:49","pubTimestamp":1733406540,"startTime":"0","endTime":"0","summary":"\"Cooler Moments\" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives.Dr. Jen Ashton, Board-Certified OBGYN, Former Chief Medical Correspondent\"I'm honored to partner with Astellas to help inspire conversation about hot flashes and night sweats due to menopause and treatment options. Managing these symptoms is not one-size-fits-all, and women should feel comfortable having an open dialogue with their healthcare providers to create a plan that's right for them. As a doctor, I've seen how hot flashes due to menopause can significantly impact women, and I know how important it is women are counseled about all of their options, both hormonal and nonhormonal.2Many women and doctors alike may not know that there are nonhormonal treatment options such as VEOZAH available, especially for women who cannot or choose not to take hormon","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mDzIeKJE_9jXg01gnDqnnQ--~B/aD0xODAwO3c9MjcwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/90cfe5e096dcfdc59723a8c260860bb5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mDzIeKJE_9jXg01gnDqnnQ--~B/aD0xODAwO3c9MjcwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/90cfe5e096dcfdc59723a8c260860bb5"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-dr-jen-ashton-launch-134900879.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-dr-jen-ashton-launch-134900879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EMPW.U","ALPMY","ALPMF","BK4007"],"gpt_icon":0},{"id":"2485435411","title":"Apellis started at equal-weight at Morgan Stanley on geographic atrophy market","url":"https://stock-news.laohu8.com/highlight/detail?id=2485435411","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485435411?lang=en_us&edition=fundamental","pubTime":"2024-11-22 00:06","pubTimestamp":1732205172,"startTime":"0","endTime":"0","summary":"mbbirdy Morgan Stanley has initiated coverage of Apellis Pharmaceuticals  at equal-weight saying that the next phase of growth in the geographic atrophy  market will be slower than the prior one. One of the pharma's key medications is Syfovre  for GA. The investment bank has a price target of $31 . Analyst Judah Frommer sees peak sales of Syfovre of $1.38B, with it splitting market share of the GA market with Astellas Pharma's  Izervay .  He noted that while Apellis believes that the two drugs are only being used by 7-8% of the total U.S. GA population, Morgan Stanley's discussions with experts indicated that initial adopters -- the physicians most likely to prescribe the drugs -- are treating only ~10%-20% of appropriate GA patients with a complement inhibitor.   \"Consistent feedback included the refrain that these drugs are approved, but that tangible benefits for patients take time to explain and are ultimately difficult to corroborate in the real world setting,\" Frommer wrote.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/169994549/image_169994549.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/169994549/image_169994549.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4316964-apellis-started-equal-weight-morgan-stanley-geographic-atrophy-market","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["LU2089284900.SGD","LU0158827948.USD","APLS","IE00BKVL7J92.USD","BK4585","LU0006306889.USD","BK4007","LU0106261372.USD","BK4581","LU1989772923.USD","LU2028103732.USD","BK4534","ALPMF","LU1548497426.USD","LU1363072403.SGD","LU0320765646.SGD","LU0106831901.USD","LU2111349929.HKD","BK4504","BK4505","LU1074936037.SGD","LU0158827781.USD","LU1720051017.SGD","LU0225283273.USD","LU0971096721.USD","LU2271345857.HKD","BK4127","ALPMY","LU1720051108.HKD","LU0267386448.USD","LU1093756325.SGD","LU1989772840.SGD","LU0314104364.USD","LU2357305700.SGD","LU2089283258.USD","LU0098860793.USD","BK4516","LU1162221912.USD","LU2023251221.USD","IE00BZ1G4Q59.USD","BK4139","LU1668664300.SGD","LU1093756168.USD","BK4588"],"gpt_icon":0},{"id":"2485465125","title":"Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2485465125","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485465125?lang=en_us&edition=fundamental","pubTime":"2024-11-21 02:00","pubTimestamp":1732125600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc.  today announced that it has entered into an agreement with Desert Oasis Healthcare , a member of Heritage Provider Network,to pilot DIGITIVA, a non-invasive digital health solution for the management of heart failure patients. In the next few weeks, eligible patients receiving care withDOHCwill begin using DIGITIVA as a new method for managing their heart health while working in partnership with their healthcare team.Patrick Keenan, DIGITIVA Program Lead, Rx+ Business Accelerator, Astellas\"Implementing DIGITIVA in a real-world setting represents a significant achievement as the first SaMD and medical device offering from Astellas in the United States. Working closely with Desert Oasis Healthcare, we look forward to demonstrating the potential of DIGITIVA to improve patient outcomes by supporting patients' ability to takea more active role in managing their health, as well as providing clinicians with personalized ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gjiuKx_AjQ8zRQBce6yKtA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a45b96e1ca7c65c41324f94bb7739f4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gjiuKx_AjQ8zRQBce6yKtA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a45b96e1ca7c65c41324f94bb7739f4e"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-announces-desert-oasis-healthcare-180000962.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-announces-desert-oasis-healthcare-180000962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","ALPMF","BK4007","HCSG","ALPMY"],"gpt_icon":0},{"id":"2484914339","title":"Astellas receives Complete Response Letter for Izervay, Apellis rallies","url":"https://stock-news.laohu8.com/highlight/detail?id=2484914339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484914339?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:01","pubTimestamp":1732014075,"startTime":"0","endTime":"0","summary":"Astellas Pharma (ALPMY) announced the Food and Drug Administration issued a Complete Response Letter regarding the supplemental new drug applicatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astellas-receives-complete-response-letter-for-izervay-apellis-rallies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astellas-receives-complete-response-letter-for-izervay-apellis-rallies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALPMY","BK4007"],"gpt_icon":0},{"id":"2483805640","title":"Should Value Investors Buy Astellas Pharma (ALPMY) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483805640","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483805640?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:40","pubTimestamp":1731422415,"startTime":"0","endTime":"0","summary":"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Astellas Pharma  is a stock many investors are watching right now. ALPMY is currently sporting a Zacks Rank of #2 , as well as a Value grade of A.Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. ALPMY has a P/S ratio of 1.72. This compares to its industry's average P/S of 3.41.Astellas Pharma Inc.  : Free Stock Analysis Report","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xMhOxlfdhVA7Ts3pP3IHyA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xMhOxlfdhVA7Ts3pP3IHyA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/value-investors-buy-astellas-pharma-144015061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMY","ALPMF","ISBC","BK4007","BK4211"],"gpt_icon":0},{"id":"2481576987","title":"Trump victory is a win for Japan equities, a loss for China – analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2481576987","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481576987?lang=en_us&edition=fundamental","pubTime":"2024-11-06 23:49","pubTimestamp":1730908152,"startTime":"0","endTime":"0","summary":"Richard Drury/DigitalVision via Getty Images The Republican presidential election win is moving financial markets to discount significant gains in the U.S. dollar and rises in the longer dated U.S. do","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303660047/image_1303660047.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303660047/image_1303660047.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4255566-trump-victory-is-a-win-for-japan-equities-a-loss-for-china-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["FXI","APELY","EWA","BK4177","FLAU","STBFY","LU0098860793.USD","LU0267386448.USD","PIN.AU","LU0225283273.USD","LU1363072403.SGD","BK4516","LU1720051017.SGD","MCHI","BK4534","TTDKY","LU0314104364.USD","BK4148","LU1989772923.USD","BK4588","IE00BZ1G4Q59.USD","PIN","EEM","BK4007","BK4523","BK4170","GXC","LU0971096721.USD","BK4504","LU0106261372.USD","FLIN","EWJ","BK4581","BK4585","LU0006306889.USD","LU0106831901.USD","LU1548497426.USD","ALPMY","OMRNY","BK4582","LU1668664300.SGD","FUJIY","TAK","LU2357305700.SGD","INDA","LU1074936037.SGD","LU1720051108.HKD","BK4127","IE00BKVL7J92.USD","LU1162221912.USD"],"gpt_icon":1},{"id":"2476218979","title":"Astellas Pharma's Cancer Drug Vyloy Gets FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2476218979","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476218979?lang=en_us&edition=fundamental","pubTime":"2024-10-19 03:29","pubTimestamp":1729279740,"startTime":"0","endTime":"0","summary":"Astellas Pharma's drug Vyloy was approved for treatment of advanced gastric and gastroesophageal junction cancer by the Food and Drug Administration.The pharmaceutical company said Friday the FDA approved the drug for use in combination with fluoropyrimidine-and-platinum-containing chemotherapy. Vyloy is intended for the first-line treatment of patients whose tumors are claudin  18.2 positive, Astellas said.The approval was based on results from Phase 3 clinical trials, and makes Vyloy the first and only CLDN18.2-targeted therapy approved in the U.S., the company said.An FDA-approved test developed by Roche Holdings is used to identify patients who may be eligible for Vyloy, Astellas said. Vyloy was also approved in Japan, the U.K., the E.U. and South Korea this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALPMY","BK4007"],"gpt_icon":0},{"id":"2476909562","title":"Astellas wins FDA nod for first-line gastric cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2476909562","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476909562?lang=en_us&edition=fundamental","pubTime":"2024-10-19 02:58","pubTimestamp":1729277901,"startTime":"0","endTime":"0","summary":"Grandbrothers Astellas Pharma (OTCPK:ALPMF) announced on Friday that the U.S. FDA approved its antibody therapy Vyloy as a first-line option for certain adults with gastric or gastroesophageal junction (GEJ) adenocarcinoma as part of a combination regimen. Vyloy is a targeted cancer","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4176595-astellas-wins-fda-nod-cancer-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4007","ALPMY","ALPMF"],"gpt_icon":0},{"id":"2476237299","title":"Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2476237299","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476237299?lang=en_us&edition=fundamental","pubTime":"2024-10-19 02:13","pubTimestamp":1729275180,"startTime":"0","endTime":"0","summary":"VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive. TOKYO, Oct. 18, 2024 /PRNewswire/ -- Astellas Pharma Inc.  today announced that the U.S. Food and Drug Administration  has approved VYLOYin combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 -negative gastric or gastroesophageal junction  adenocarcinoma whose tumors are claudin  18.2 positive as determined by an FDA-approved test.1 VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.The approval is based on results from the Phase 3 SPOTLIGHTand GLOWclinical trials.2,3 The SPOTLIGHT study evaluated VYLOY plus mFOLFOX6  compared to placebo plus mFOLFOX6. The GLOW study evaluated VYLOY plus CAPOX  compared to pla","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YG3qycgoBeD1Ep4Cch49aQ--~B/aD0xMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YG3qycgoBeD1Ep4Cch49aQ--~B/aD0xMTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-vyloy-zolbetuximab-clzb-approved-181300338.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-vyloy-zolbetuximab-clzb-approved-181300338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","IHC","IE00B66KJ199.SGD","IE00B19Z4B17.USD","ALPMY","ALPMF","BK4007","BK4157","IE00B7SZL793.SGD","PFS","IRR","BK4162","OS","BK4195","BK4097","IE0031619046.USD","AEIS","CDC"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-01","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1698811200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1683000000000}}}